Latest news with #EV71
BusinessToday
15 hours ago
- Health
- BusinessToday
Facts Prevention Tips For Hand, Foot And Mouth Disease
Amid the excitement of school holidays, parents and caregivers should remain extra cautious as the recent surge in Hand, Foot and Mouth Disease (HFMD) cases reported nationwide underscores the importance of remaining vigilant of the warning signs associated with the illness. Though it is common during this time of the year, Sunway Medical Centre (SMC) Paediatric Infectious Disease Consultant Dr Ch'ng Tong Wei said the current scale of transmission is alarming, necessitating heightened awareness and preventive measures. 'As a paediatric infectious disease specialist, I have observed a rise in hospital referrals, concerned parental inquiries, and requests for guidance from preschools and kindergartens on outbreak management,' she said. Understanding HFMD HFMD is a highly contagious viral infection predominantly affecting children under five. The illness typically presents with fever, sore throat, reduced appetite, painful oral ulcers and rash on the hands, feet and occasionally buttocks. Most cases are mild, with recovery within seven to 10 days. However, a small number of cases, usually linked to EV71 virus strain, may lead to complications such as viral meningitis, encephalitis (brain inflammation) and cardiopulmonary complications. The good news is that these complications remain very rare, she said. Current Outbreak Situation According to the Health Ministry, HFMD cases throughout sees a 266% increase in infections compared to the same period last year. The number of HFMD cases in Malaysia has risen to 99,601 as of the 17th epidemiological week this year compared to 27,236 cases during the same period last year. No fatalities were reported linked to the disease. The ministry said 10,421 cases this year or 10% were outbreak-related, while 90% or 89,180 cases occurred sporadically. Prevention Tips for Parents and Schools 'Since there is no specific treatment for HFMD, prevention and comfort care are essential,' she said. The measures to be taken into consideration are: Keep sick children at home: Children with HFMD should remain at home until all blisters have dried and they are fever-free for at least 24 hours. This is the most effective way to stop the virus from spreading. Handwashing is critical. Children with HFMD should remain at home until all blisters have dried and they are fever-free for at least 24 hours. This is the most effective way to stop the virus from spreading. Handwashing is critical. Practice good hygiene: Teach children to wash their hands thoroughly with soap, especially after using the toilet and before eating. Disinfect toys and surfaces regularly with chlorine-based or antiviral disinfectants. Teach children to wash their hands thoroughly with soap, especially after using the toilet and before eating. Disinfect toys and surfaces regularly with chlorine-based or antiviral disinfectants. Avoid high-risk areas during outbreaks: Temporarily limit visits to playgrounds, childcare centres or crowded spaces during outbreaks where transmissions are more likely. Avoid sharing utensils, towels or personal items. Temporarily limit visits to playgrounds, childcare centres or crowded spaces during outbreaks where transmissions are more likely. Avoid sharing utensils, towels or personal items. Provide comfort care for infected children: Offer soft foods, cool drinks and administer paracetamol if needed for fever or pain. Seeking Medical Attention She said most children recover without complications, but consulting a doctor is paramount if the child exhibits symptoms such as refusal to eat or drink (risk of dehydration), high fever (above 39°C) lasting more than 2 days and lethargy, irritability or altered consciousness. Severe cases may require hospitalisation for intravenous hydration, antipyretics and close neurological monitoring, she added. Curbing HFMD Outbreak is a Shared Responsibility The recent rise in cases across Selangor, Johor, Perak and other states is a reminder that we must remain vigilant, not just in hospitals, but as a community. We are monitoring the situation closely with its paediatric teams, nurses and infection control unit are working hand-in-hand to support parents and manage cases safely and efficiently. By staying informed and adopting preventive measures, Dr Ch'ng believes we can collectively reduce transmission and safeguard our children's health. 'Together, we can protect our children and reduce transmission by adhering to the guidelines. For further inquiries or medical advice, please consult a healthcare professional.' Related
Business Wire
23-05-2025
- Business
- Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the ' Notification Letter ') from Nasdaq Listing Qualifications (' Nasdaq '), stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) since the Company did not timely file its annual report on Form 20-F for the year ended December 31, 2024 (the ' 2024 Annual Report '). Pursuant to the Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Notification Letter, or until July 15, 2025, to submit a plan to regain compliance (the ' Compliance Plan '). If Nasdaq accepts the Compliance Plan, it may grant the Company an exception until November 11, 2025, to regain compliance. If Nasdaq does not accept the Compliance Plan, the Company will have the opportunity to appeal that decision to a hearing panel under Nasdaq Listing Rule 5815(a). As previously disclosed, on April 15, 2025, Grant Thornton Zhitong Certified Public Accountants LLP (' Grant Thornton ') notified the Company that it had resigned as the Company's independent registered public accounting firm. The Company's audit committee has commenced and is diligently conducting a process to evaluate and select a new independent registered public accounting firm so that the 2024 Annual Report can be filed as soon as practicable. The Company intends to submit the Compliance Plan within the prescribed 60-day period ending July 15, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac ®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive ®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive ®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1 ®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu ®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions, including the Company's statements related to the Compliance Plan, and timing and actions taken to regain compliance with Nasdaq listing rules. Such statements are based upon the Company's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of engaging independent auditors and completion of the audits of required fiscal periods, completion and filing of the 2024 Annual Report, the Compliance Plan, and actions taken to regain compliance with the Nasdaq listing rules, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Yahoo
23-05-2025
- Business
- Yahoo
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
BEIJING, May 23, 2025--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the "Notification Letter") from Nasdaq Listing Qualifications ("Nasdaq"), stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) since the Company did not timely file its annual report on Form 20-F for the year ended December 31, 2024 (the "2024 Annual Report"). Pursuant to the Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Notification Letter, or until July 15, 2025, to submit a plan to regain compliance (the "Compliance Plan"). If Nasdaq accepts the Compliance Plan, it may grant the Company an exception until November 11, 2025, to regain compliance. If Nasdaq does not accept the Compliance Plan, the Company will have the opportunity to appeal that decision to a hearing panel under Nasdaq Listing Rule 5815(a). As previously disclosed, on April 15, 2025, Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") notified the Company that it had resigned as the Company's independent registered public accounting firm. The Company's audit committee has commenced and is diligently conducting a process to evaluate and select a new independent registered public accounting firm so that the 2024 Annual Report can be filed as soon as practicable. The Company intends to submit the Compliance Plan within the prescribed 60-day period ending July 15, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions, including the Company's statements related to the Compliance Plan, and timing and actions taken to regain compliance with Nasdaq listing rules. Such statements are based upon the Company's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of engaging independent auditors and completion of the audits of required fiscal periods, completion and filing of the 2024 Annual Report, the Compliance Plan, and actions taken to regain compliance with the Nasdaq listing rules, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Sinovac Biotech YangTel: +86-10-8279 9779Email: ir@ Sign in to access your portfolio
The Sun
22-05-2025
- Health
- The Sun
HFMD situation in Selangor under control, showing signs of recovery
SHAH ALAM: The hand, foot and mouth disease (HFMD) situation in Selangor is under control and showing early signs of recovery following coordinated control measures. State Public Health and Environment Committee chairman Jamaliah Jamaluddin said Selangor recorded 39,233 HFMD cases as of Epidemiological Week 19 (EW19/2025), which ended on May 10. She noted a significant rise in cases between EW1 5 and EW19, particularly after the first week of the Aidilfitri celebration. 'This increase is attributed to more active movement of people, social visits, close interactions among children in crowded settings such as relatives' homes, and the sharing of food and toys. 'Another factor is the lax screening at childcare facilities, which has hampered efforts to detect and isolate symptomatic children,' she said in a statement today. Jamaliah added that nine cases involving the Enterovirus 71 (EV71) variant were reported - seven in Sabak Bernam and two in Hulu Langat. One patient in Sabak Bernam was hospitalised and has since fully recovered, while the others received outpatient treatment. She said most HFMD clusters occurred in childcare and early education centres, including nurseries, kindergartens, preschools and tuition centres (42.8 per cent), followed by primary schools (five per cent), day care centres (three per cent), and secondary schools (0.2 per cent). The remaining 49 per cent were home-based. As of EW 19, a total of 627 premises were closed - 192 voluntarily and 435 under the Prevention and Control of Infectious Diseases Act 1988 (Act 342). 'Voluntary closures involved 63 nurseries, 81 kindergartens, 25 government-run preschools (tabika), 15 preschools, one care centre, six primary schools and one other premises. 'Enforced closures included 168 nurseries, 157 kindergartens, 69 tabika, 29 preschools, two care centres and 10 primary schools,' she said. Jamaliah said the Selangor Health Department has instructed for increased sample collection, especially at institutions and among hospitalised patients, to improve monitoring and detection of virus variants. She advised parents not to send symptomatic children to care or educational centres and to ensure they remain at home until fully recovered to prevent further transmission. Operators of early childhood education centres are also urged to refuse entry to symptomatic children, conduct health screenings at entry points and maintain a high level of hygiene. She added that the state government, through the Public Health Committee, will distribute educational materials on HFMD, including information on symptoms and preventive measures, to nurseries and kindergartens in high-incidence areas. 'This initiative aims to strengthen community awareness and preparedness. The state government remains committed to working closely with the Selangor Health Department and all relevant agencies to control the outbreak effectively,' she said.
The Sun
22-05-2025
- Health
- The Sun
Selangor HFMD cases under control, signs of recovery
SHAH ALAM: The hand, foot and mouth disease (HFMD) situation in Selangor is under control and showing early signs of recovery following coordinated control measures. State Public Health and Environment Committee chairman Jamaliah Jamaluddin said Selangor recorded 39,233 HFMD cases as of Epidemiological Week 19 (EW19/2025), which ended on May 10. She noted a significant rise in cases between EW1 5 and EW19, particularly after the first week of the Aidilfitri celebration. 'This increase is attributed to more active movement of people, social visits, close interactions among children in crowded settings such as relatives' homes, and the sharing of food and toys. 'Another factor is the lax screening at childcare facilities, which has hampered efforts to detect and isolate symptomatic children,' she said in a statement today. Jamaliah added that nine cases involving the Enterovirus 71 (EV71) variant were reported - seven in Sabak Bernam and two in Hulu Langat. One patient in Sabak Bernam was hospitalised and has since fully recovered, while the others received outpatient treatment. She said most HFMD clusters occurred in childcare and early education centres, including nurseries, kindergartens, preschools and tuition centres (42.8 per cent), followed by primary schools (five per cent), day care centres (three per cent), and secondary schools (0.2 per cent). The remaining 49 per cent were home-based. As of EW 19, a total of 627 premises were closed - 192 voluntarily and 435 under the Prevention and Control of Infectious Diseases Act 1988 (Act 342). 'Voluntary closures involved 63 nurseries, 81 kindergartens, 25 government-run preschools (tabika), 15 preschools, one care centre, six primary schools and one other premises. 'Enforced closures included 168 nurseries, 157 kindergartens, 69 tabika, 29 preschools, two care centres and 10 primary schools,' she said. Jamaliah said the Selangor Health Department has instructed for increased sample collection, especially at institutions and among hospitalised patients, to improve monitoring and detection of virus variants. She advised parents not to send symptomatic children to care or educational centres and to ensure they remain at home until fully recovered to prevent further transmission. Operators of early childhood education centres are also urged to refuse entry to symptomatic children, conduct health screenings at entry points and maintain a high level of hygiene. She added that the state government, through the Public Health Committee, will distribute educational materials on HFMD, including information on symptoms and preventive measures, to nurseries and kindergartens in high-incidence areas. 'This initiative aims to strengthen community awareness and preparedness. The state government remains committed to working closely with the Selangor Health Department and all relevant agencies to control the outbreak effectively,' she said.
